Nyxoah (NASDAQ:NYXH) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Nyxoah (NASDAQ:NYXH) posted its quarterly earnings data on Wednesday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.20), Zacks reports. The firm had revenue of $8.76 million for the quarter, compared to analyst estimates of $8.64 million. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%.

Here are the key takeaways from Nyxoah’s conference call:

• U.S. commercialization accelerated: Q2 worldwide revenue rose 21% sequentially to €7.7 million, including 22% U.S. growth to €5.2 million. Active U.S. accounts doubled to 180, while 427 patients were under prior authorization entering Q3, up 77% sequentially.
• Reimbursement support strengthened: CMS proposed 2027 reimbursement increases of approximately 12% for hospital outpatient facilities and 15% for ambulatory surgery centers for Genio procedures. Nyxoah also reported a 100% prior-authorization approval rate across commercial, Medicare Advantage, and WISeR-submitted Medicare patients.
• Balance sheet improved materially: The company secured $110 million through a $95 million equity raise and a $15 million EIB loan drawdown, providing funding to expand its U.S. sales organization and patient-funnel initiatives.
• Full-year guidance was maintained: Nyxoah continues to expect 2026 revenue of €36 million–€40 million and gross margin of 60%–62%, with U.S. revenue expected to grow sequentially in both Q3 and Q4 while international revenue remains broadly stable.
• Operating expenses remain elevated: Q2 operating expenses increased to €25.1 million, including higher selling, general and administrative costs from the U.S. commercial build-out, while the company reported a €20.6 million operating loss. Full-year operating-expense guidance increased by €1 million to €99 million–€102 million due to a one-time share-based compensation charge.

Nyxoah Stock Up 12.2%

NASDAQ NYXH traded up $0.16 during trading hours on Friday, hitting $1.47. 82,956 shares of the company traded hands, compared to its average volume of 143,354. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 2.38. The business’s 50-day moving average is $1.66 and its 200-day moving average is $2.95. The stock has a market capitalization of $56.98 million, a price-to-earnings ratio of -0.58 and a beta of 1.62. Nyxoah has a twelve month low of $1.26 and a twelve month high of $8.59.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Heights Capital Management Inc. acquired a new stake in shares of Nyxoah in the 4th quarter valued at approximately $3,575,000. Shay Capital LLC acquired a new position in Nyxoah during the second quarter worth $374,000. Citadel Advisors LLC acquired a new position in Nyxoah during the third quarter worth $98,000. Bank of America Corp DE raised its position in Nyxoah by 152.7% during the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock worth $91,000 after acquiring an additional 12,012 shares in the last quarter. Finally, Deutsche Bank AG raised its position in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after acquiring an additional 10,000 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NYXH shares. Oppenheimer set a $4.00 target price on Nyxoah in a research note on Thursday. Wall Street Zen raised shares of Nyxoah to a “hold” rating in a research note on Saturday, August 1st. Piper Sandler reiterated an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a report on Thursday. Weiss Ratings downgraded shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Finally, Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a research report on Thursday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nyxoah presently has a consensus rating of “Hold” and a consensus price target of $5.26.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.